No products in the cart.

Home / Human Rights / “LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

“LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

December 15, 2023 by Lezzie 0 comments Human Rights

“LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

TOKYO and CAMBRIDGE, Mass., Dec 14, 2023 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI Intravenous Infusion” (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List.LEQEMBI received manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in Japan on September 25…
Read More

PREVThe Center for Adoption Support and Education (C.A.S.E.) Joins HRC and Record Number of Partners Working on LGBTQ+ Inclusivity

NEXTPPL Announces $62 Million Q4 Distribution, Drawing Revenue from a Record 63 CMOs